Biotech News

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Black Diamond Therapeutics (BDTX)Black Diamond Therapeutics2026-06-25 13:46 ESTClinical readout

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to date PFS data for 1L NSCLC patients expected in Q2 2026; Company

Open original release

Related news

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

View all latest news

Black Diamond Therapeutics

Black Diamond Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

BDTXBlack Diamond Therapeutics2026-06-26 08:47 EST

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

BDTXBlack Diamond Therapeutics2026-06-26 08:47 EST

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

BDTXBlack Diamond Therapeutics2026-06-26 08:47 EST

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-26 08:47 EST

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-26 08:47 EST

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States